Balaji Amines Limited (BALAMINES) AI Stock Analysis

• Market Cap: ₹45.89B
• Dividend Yield: 0.75%
• Average Volume (3M): 3.22K
• Price to Earnings (P/E): 30.1
• Beta (1Y): 1.56
• Revenue Growth: -12.28%
• EPS Growth: -22.10%
• Country: IN
• Employees: 1,084
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): 11.73
• Shares Outstanding: 32,401,000
• 10 Day Avg. Volume: 4,117
• 30 Day Avg. Volume: 3,223
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,634.00
• Price Target Upside: 15.38% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 59 Neutral
• Price Target: ₹1,634.00 ▲(15.38% Upside)

Balaji Amines has a strong financial foundation but faces challenges in revenue growth. Technical indicators point to bearish momentum, with the stock trading below key moving averages. The valuation metrics indicate the stock may be overvalued, creating a cautious outlook unless growth prospects improve.

Balaji Amines Limited Business Overview & Revenue Model

Company Description

Balaji Amines Limited engages in the manufacture and sale of methylamines, ethylamines, and derivatives of specialty chemicals and pharma excipients in India. The company operates through three segments: Amines & Speciality Chemicals, Hotel, and CFL Lamps. It offers monomethylamine, dimethylamine, trimethylamine, monoethylamine, diethylamine, triethylamine, dimethyl and diethyl amino ethanol; and specialty chemicals, including N-methyl pyrrolidone, morpholine, 2-pyrrolidone, N-ethyl-2-pyrrolidone, gamma-butyrolactone, dimethylformamide, and acetonitrile. The company also provides derivatives comprising di-methyl acetamide, di-methyl amine hydrochloride, tri-methyl amine hydrochloride, di-ethyl amine hydrochloride, tri-ethyl amine hydrochloride, di-methyl urea, and choline chloride; and pharma excipients, such as poly vinyl pyrrolidone. It serves pharmaceutical, agrochemical, paint and resin, animal feed, oil and gas, rubber cleaning chemical, dye and textile, and water treatment chemical industries. In addition, the company operates Balaji Sarovar, a hotel in Solapur, Maharashtra; and manufactures and sells CFL lamps. It also exports its products to the United States, Europe, China, Turkey, Korea, Malaysia, Kuwait, and internationally. The company was incorporated in 1988 and is based in Hyderabad, India.

How the Company Makes Money

Balaji Amines Limited generates revenue through the manufacturing and sale of a diverse portfolio of chemical products, primarily focusing on aliphatic amines and their derivatives. The company's key revenue streams include sales to the pharmaceutical industry, which uses these chemicals as intermediates in drug production, and the agrochemical industry for use in pesticides. Additionally, BALAMINES serves the water treatment sector with products like morpholine. Its revenue model is bolstered by its strong manufacturing capabilities and strategic partnerships with industries that require specialized chemical products. The company benefits from a robust distribution network and a focus on innovation to meet the growing demands of its clients, contributing to its financial performance.

Balaji Amines Limited Financial Statement Overview

Summary

Balaji Amines is financially sound with a stable balance sheet and consistent cash flow generation. The company has maintained profitability despite revenue pressures, signaling good operational efficiency. To ensure long-term growth, management should address revenue challenges and continue to optimize cash flow.

Income Statement

Balaji Amines has shown resilience in its income statement despite revenue fluctuations. The Gross Profit Margin and Net Profit Margin have been reasonably stable, reflecting effective cost management. However, the recent contraction in revenue and net income suggests challenges in market conditions or competition.

Balance Sheet

The balance sheet is strong, with a low Debt-to-Equity Ratio indicating conservative financial leverage. The equity ratio is robust, showcasing a solid capital structure. However, the company should watch for any increase in liabilities that could affect its financial stability.

Cash Flow

Cash flow metrics reveal effective cash management, with positive Free Cash Flow indicating the ability to sustain operations and investments. While the Operating Cash Flow to Net Income ratio is healthy, the company must focus on improving cash flow growth to support future expansions.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	14.58B	13.97B	23.38B	16.42B	23.20B	13.11B
Gross Profit	5.95B	4.88B	8.39B	3.79B	8.57B	5.39B
EBITDA	3.04B	2.65B	6.24B	3.53B	6.36B	3.79B
Net Income	1.85B	1.58B	3.26B	2.05B	3.68B	2.38B
Balance Sheet
Total Assets	0.00	22.52B	19.63B	21.46B	18.75B	13.10B
Cash, Cash Equivalents and Short-Term Investments	3.17B	3.54B	3.09B	3.31B	381.27M	173.23M
Total Debt	0.00	110.27M	575.74M	196.97M	1.01B	1.27B
Total Liabilities	-19.45B	2.34B	2.65B	2.53B	5.60B	4.00B
Stockholders Equity	19.45B	18.45B	15.54B	17.22B	12.50B	8.94B
Cash Flow
Free Cash Flow	0.00	874.82M	2.62B	-303.24M	842.07M	-221.07M
Operating Cash Flow	0.00	2.73B	3.82B	2.24B	2.32B	1.10B
Investing Cash Flow	0.00	-1.61B	-1.86B	-1.64B	-1.34B	-615.89M
Financing Cash Flow	0.00	-447.73M	-812.33M	-749.66M	-662.68M	-374.51M

Balaji Amines Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1416.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BALAMINES, the sentiment is Negative. The current price of 1416.25 is below the 20-day moving average (MA) of 1491.80, below the 50-day MA of 1562.27, and below the 200-day MA of 1537.88, indicating a bearish trend. The MACD of -25.72 indicates Positive momentum. The RSI at 32.34 is Neutral, neither overbought nor oversold. The STOCH value of 19.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BALAMINES.

Balaji Amines Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROSSARI	64 Neutral	34.89B	25.93	11.50%	0.08%	11.77%	-1.14%
NEOGEN	62 Neutral	39.91B	119.70	4.41%	0.07%	11.14%	-11.15%
ALKYLAMINE	62 Neutral	100.73B	54.93	13.27%	0.51%	10.29%	26.09%
BALAMINES	59 Neutral	₹45.89B	30.14	―	0.75%	-12.28%	-22.10%
FAIRCHEMOR	54 Neutral	10.13B	110.13	7.28%	0.96%	-19.46%	-80.73%
ANURAS	54 Neutral	125.65B	98.34	3.28%	0.07%	24.37%	29.82%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%